Feeling uncertain about how to ensure full compliance with QPPV and veterinary pharmacovigilance? With evolving regulations and increasing scrutiny, many marketing-authorisation holders struggle to guarantee constant oversight and rapid response. Fortunately, by partnering with a professional 24/7 QPPV service designed for veterinary pharmacovigilance, you gain reliable expertise and seamless support to meet regulatory demands and streamline your safety system.

What does “continuous oversight” mean for QPPV and veterinary pharmacovigilance systems?

When you engage a dedicated service in the field of veterinary pharmacovigilance, “continuous oversight” means that a responsible function (the QPPV and veterinary pharmacovigilance system) is proactively monitoring safety and compliance at all times. Under the regulatory framework of European Medicines Agency (EMA) for veterinary medicinal products, marketing-authorisation holders (MAHs) must have a pharmacovigilance system in place which includes a designated Qualified Person for Pharmacovigilance (QPPV) and a signed statement confirming the QPPV has the necessary means to fulfil their tasks.
Continuous oversight covers aspects such as maintaining the Pharmacovigilance System Master File (PSMF), ensuring records and databases are active, monitoring adverse event reports, signal detection and evaluation, and ensuring that internal processes (SOPs, training, audits) are active and effective.
For MAHs, partnering with a professional service to manage 24/7 coverage means they can meet the expectation of “permanently and continuously at disposal” of the QPPV and related safety functions, thereby reducing regulatory risk and operational burden.
In essence, continuous oversight is the backbone of any robust system for QPPV and veterinary pharmacovigilance — it means being ready, responsive and compliant from product launch through lifecycle management.

How can a dedicated 24/7 QPPV service support your veterinary pharmacovigilance compliance?

When you engage a partner such as Billev Pharma East for dedicated 24/7 QPPV support, you place compliance and operational readiness at the heart of your QPPV and veterinary pharmacovigilance strategy. The regulatory framework under Regulation (EU) 2019/6 and Commission Implementing Regulation (EU) 2021/1281 emphasizes that MAHs must ensure that the QPPV and pharmacovigilance system are continuously available.
A full-service 24/7 QPPV provider typically offers: round-the-clock access to the QPPV or designated back-up, monitoring and management of adverse event and signal processes, preparation for regulatory inspections, and support for data submission into systems like EVVet. Such proactive service allows MAHs to stay ahead of requirements, respond quickly to emerging safety signals and demonstrate regulatory readiness.
By outsourcing to a specialised provider, you reduce internal resource strain, gain access to expert knowledge in veterinary pharmacovigilance, and align your operations with best-practice standards while maintaining compliance. In turn, this supports the MAH’s ability to focus on product development and market growth, while leaving the functional responsibilities of QPPV and veterinary pharmacovigilance in trusted hands.

Why must a marketing-authorisation holder ensure the QPPV in veterinary pharmacovigilance has back-up arrangements?

It is insufficient for a MAH to appoint a QPPV and then rely solely on that single individual. Regulatory expectation is clear: for QPPV in veterinary pharmacovigilance, there must be documented back-up arrangements so that the function remains continuously available — even during absence due to illness, leave or resource constraints. The EMA  VGVP guidelines emphasise that the PSMF should include the name, contact details and place of operation of the QPPV and ensure the system is able to respond at all times. If a QPPV is not reachable, a delay in adverse incident evaluation or regulatory submission may occur, raising compliance risk. By ensuring clear succession planning, functional redundancy and contractual arrangements (including service-providers or internal backups), the MAH protects its pharmacovigilance system and remains aligned with obligations for veterinary medicinal products.
In practical terms, establish a designated deputy or external partner, maintain escalation protocols and keep documentation updated in the PSMF. The presence of back-up mechanisms reinforces that the MAH takes its QPPV in veterinary pharmacovigilance obligations seriously.

Ensuring robust back-up for the QPPV in veterinary pharmacovigilance

To maintain compliance, a marketing-authorisation holder (MAH) must clearly define back-up arrangements for the QPPV in veterinary pharmacovigilance in the PSMF (Pharmacovigilance System Master File). For example, guidance from the European Medicines Agency (EMA) emphasizes that the QPPV must be “permanently and continuously at the disposal” of the MAH and that any absence of the QPPV must be covered by an adequately qualified deputy.
Such arrangements typically include a documented role description of the deputy, access to the same databases and safety-process infrastructure as the principal QPPV, and clearly defined escalation procedures. This ensures the QPPV in veterinary pharmacovigilance system remains uninterrupted—even during holidays, illness, or transitions—and significantly reduces regulatory risk.

What regulatory checkpoints should your external QPPV provider meet for veterinary pharmacovigilance?

When engaging an external provider for QPPV and veterinary pharmacovigilance, you must verify several regulatory checkpoints. First, the provider must demonstrate that its QPPV (or team) is suitably qualified to cover veterinary products under the veterinary medicines regulation. EMA guidance states the MAH must have a system in place and must maintain the PSMF, with clear roles and responsibilities for the QPPV.
Key checkpoints include: residency and availability of the QPPV (within the EEA, with continuous access), documented SOPs and quality management system, ability to submit data to EVVet (or equivalent), defined signal-management processes, audit history and inspection readiness, and back-up structures for continuity.
Due diligence should also review contractual terms (e.g., when tasks are outsourced, the MAH must verify quality of performance) and the provider’s track record in veterinary pharmacovigilance. Ensuring these checkpoints are met helps the MAH maintain compliance, operational efficiency and readiness for regulatory scrutiny.

How does the role of the QPPV in veterinary pharmacovigilance intersect with signal-management and incident response?

The responsibility of QPPV in veterinary pharmacovigilance extends well beyond administrative oversight; it encompasses active engagement in signal-management and incident response. Under Regulation (EU) 2019/6 and detailed in the EMA Q&A for veterinary pharmacovigilance inspections, MAHs must conduct continuous signal monitoring throughout the lifecycle of a veterinary medicinal product.
Signal-management involves collecting suspected adverse reaction reports, analysing trends, assessing risks, and initiating corrective actions (which may include label changes, restriction of use, or withdrawal). The QPPV is ideally placed to oversee this process, ensure the required documentation is current (PSMF, databases), liaise with national competent authorities, and ensure timely escalation.
In an incident scenario – for example a sudden cluster of adverse events, environmental concerns or off-label misuse – the QPPV must coordinate multidisciplinary response, including regulatory submission, communication with stakeholders, documentation of actions taken and evaluation of mitigation measures. This real-time role emphasises why robust QPPV coverage is integral to any effective veterinary pharmacovigilance system.

How active signal-management supports the QPPV in veterinary pharmacovigilance

Effective signal-management is a core responsibility of the QPPV in veterinary pharmacovigilance, and regulatory guidance under Regulation (EU) 2019/6 (and its implementing acts) makes this explicit. The European Medicines Agency defines a safety signal as “information on a new or known adverse event that may be caused by a medicine and requires further investigation.”
In practice, the QPPV must oversee the collection of reports from spontaneous reporting, literature, observational studies and other sources; assess the data for trends or patterns; and initiate regulatory-appropriate action (such as label changes or communication to veterinarians). By actively engaging in signal-management, the QPPV in veterinary pharmacovigilance helps protect animal and public health, and demonstrates to authorities that the pharmacovigilance system is operational and compliant.

When should you evaluate outsourcing to a 24/7 QPPV service for veterinary pharmacovigilance efficiency?

Outsourcing a 24/7 QPPV service becomes highly relevant when internal resources cannot guarantee continuous coverage, when the geographic spread of products is global, or when regulatory complexity is high. With QPPV and veterinary pharmacovigilance obligations increasing under newer regulations (e.g., Regulation (EU) 2019/6), many MAHs find that external specialised support delivers improved efficiency and compliance.
Look for triggers such as: multiple product lines across regions, limited internal pharmacovigilance team size, upcoming regulatory inspections, or investment in newer markets. Outsourcing gives you access to specialist skills, established systems, faster response times and mitigates risk of non-compliance.
From a strategic viewpoint, outsourcing allows your internal team to focus on core product development and market access, while ensuring the operational backbone of your QPPV and veterinary pharmacovigilance system is handled consistently, proactively and in line with best practice.

What contractual and audit-requirements apply when engaging a 24/7 QPPV partner in veterinary pharmacovigilance?

When partnering with an external 24/7 provider for QPPV and veterinary pharmacovigilance, clear contractual and audit requirements must be established from the outset. The EMA’s veterinary pharmacovigilance Q&As state that when tasks are outsourced, the MAH must be able to verify the quality of outsourced tasks and have a pharmacovigilance agreement in place with minimum information outlined.
Key contractual elements include: scope of services (24/7 availability, back-up QPPV, signal-management, database submission), performance indicators (KPI for response times, coverage), roles and responsibilities, audit rights for the MAH, confidentiality and data security clauses, reporting obligations, and termination/corrective measure clauses. An audit plan should include initial qualification of the provider, periodic reviews, internal audit reporting from the provider to the MAH, and readiness for regulatory inspection.
Ensuring these contractual and audit frameworks are in place gives the MAH confidence that the external partner is not only operationally delivering but also aligning with regulatory expectations and safeguarding the integrity of the entire pharmacovigilance system.

Read also:

• What is the veterinary adverse reporting guideline and how should It be followed?
• Veterinary pharmacovigilance outsourcing: boost compliance and efficiency
• What are the main methods used in veterinary risk management?

Sources: 1 – European Medicines Agency. (2022, January 28). Guideline on veterinary good pharmacovigilance practices (VGVP): Module – Pharmacovigilance systems, their quality management systems and pharmacovigilance system master-files, 2 – European Medicines Agency. (n.d.). Pharmacovigilance (veterinary medicines), 3 – GOV.UK. (2025, July 4). Guideline I: Pharmacovigilance systems, including risk management – Veterinary Medicines, 4 – European Medicines Agency. (n.d.). Veterinary pharmacovigilance inspections: Q&As, 5 – European Medicines Agency. (n.d.). Signal management (veterinary medicines), 6 – GOV.UK. (2024, December 16). Implementation explainer: Pharmacovigilance – Veterinary Medicines Regulation (VMR), 7 – Sidley Austin LLP. (2025, September). Evolving veterinary pharmacovigilance frameworks in Europe: What industry needs to know.